Physician profile

Caleb Mangum

General Practice (Dentist) · Frisco, TX

NPI 1619454287

$250.20

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$115.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dentsply Sirona INC $100.94 2022-2024 Cavitron, Mis, Primescan Connect
Align Technology, INC. $48.38 2023-2024 Invisalign, Itero Element 5d Plus
Implant Direct Sybron International LLC $36.41 2019-2021
Orapharma, A Division of Bausch Health US, LLC $20.88 2024 Arestin
Biohorizons Implant Systems INC. $19.43 2019
Philips North America LLC $12.15 2019
Dexcel Pharma Technologies LTD. $12.01 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Caleb Mangum

$250.20

in general payments reported 2019-2025

Years
2019-2024
Top company
Dentsply Sirona INC

https://glasscript.com/doctor/4310023/caleb-mangum

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.